



Ind-Swift LABORATORIES Limited

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswifflabs.com Website : www.indswifflabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 1st August, 2025

To
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

To
Department of Corporate Services,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Subject: Outcome of the meeting of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma’am,

With reference to the captioned subject and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good office that the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“**the Company**”) at their meeting held on Friday, August 01, 2025, has, inter alia, considered and approved the allotment of 11,00,000 Equity Shares of face value of ₹ 10/- each pursuant to the conversion of 11,00,000 Fully Convertible Warrants (“**Warrants**”), allotted on August 30, 2024, at an issue price of ₹ 121/- each to Essix Biosciences Limited, belonging to Promoter & Promoter Group on preferential basis.

Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stands increased to ₹73,48,68,600/- (Rupees Seventy-Three Crore Forty-Eight Lakh Sixty-Eight Thousand and Six Hundred Only) divided into 7,34,86,860 (Seven Crore Thirty-Four Lakh Eighty-Six Thousand Eight Hundred and Sixty) Equity Shares of face value of ₹10/- each.

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the Preferential Allotment is enclosed as Annexure A.

The meeting of the Preferential Issue Committee of the Board of Directors was commenced at 11:45 A.M. and concluded at 12:30 P.M.

This is for your information and records.

Thanking you,
Yours faithfully,
For Ind-Swift Laboratories Limited



Pardeep Verma
VP-Corporate Affairs & Company Secretary



Ind-Swift LABORATORIES Limited

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswifflabs.com Website : www.indswifflabs.com
CIN No. L24232CH1995PLC015553



Annexure A

Details on Preferential Allotment in terms of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

S. No.	Particulars	Disclosures
1.	Type of securities proposed to be issued	Equity shares with face value of ₹10/- each pursuant to the conversion of warrants.
2.	Type of issuance	Preferential allotment under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law.
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Allotment of 11,00,000 equity shares of face value ₹10/- each, pursuant to conversion of 11,00,000 Fully Convertible Warrants (“Warrants”), against the receipt of the balance subscription amount aggregating to ₹ 9,98,25,000/-
4.	Name and number of the Investor(s)	Essix Biosciences Limited
5.	Post allotment of securities- outcome of the subscription	Pursuant to the aforesaid allotment, the issued, subscribed and paid-up share capital of the Company stands increased in the manner as set out in the letter above.
6.	Issue price / allotted price (in case of convertibles)	Rs. 121/- (Rupees One Hundred Twenty-One Only) per Equity Share.
7.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	The allottee mentioned above have exercised their rights and converted their 11,00,000 Warrants into Equity Shares.